Submission declined on 11 May 2026 by BlueStaticHorse (talk). This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove: promotional language: see Words to watch; personal commentary: opinions or direct addresses to the reader; informal language. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by BlueStaticHorse 26 days ago. Last edited by Citation bot 22 days ago. Reviewer: Inform author. This draft has been resubmitted and is currently awaiting re-review.

• Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Csabbagh (talk) 17:15, 11 May 2026 (UTC)

Trimi Health is an American telehealth company that operates

within a category of online providers that emerged in 2023–2024 dispensing

compounded versions of [[Glucagon-like peptide-1 receptor

agonist|GLP-1 receptor agonist]] medications during a federal shortage of the

branded products.^[1][2] The company

is headquartered in New York City and was incorporated in May 2024.^[3][4]

The shortage and resulting compounding window produced a substantial industry of

online telehealth platforms — including Hims & Hers Health, Ro, Henry Meds, Mochi

Health, and Trimi Health — that paired licensed prescribers with 503A pharmacy

partners. The FDA has repeatedly issued public warnings about consumer-safety risks

associated with this category, including dosing errors, salt-form contamination, and

online sellers operating outside legitimate medical practice.^[5] The agency removed tirzepatide from the shortage list in late 2024,

narrowing the regulatory basis for compounding it, and has continued to issue

guidance affecting which 503A activities remain permitted.<ref name="fda-shortage"/>

Clinical care on the platform is delivered by medical doctors and other licensed

prescribers contracted through Beluga Health, a multistate [[management services

organization]] (MSO) that serves as a clinician network for telehealth platforms.

^[6] Beluga Health holds LegitScript healthcare merchant

certification, is ISO/IEC 27001 and SOC 2 compliant, and licenses

prescribers in all 50 U.S. states and Washington, D.C.^[6]

Provider profiles published on the Trimi Health website include Asad Niazi, M.D.,

M.P.H., listed as a prescribing clinician within the Beluga Health network.^[7]Trimi Health itself holds active LegitScript Healthcare Merchant Certification,

a third-party compliance program used by major advertising and payment platforms to

verify that telehealth merchants meet applicable U.S. legal and regulatory

standards.^[8]

Trimi Health operates on a recurring-subscription model with annual, semi-annual,

quarterly, and monthly billing options. The plans bundle medication, clinician

access, and shipping into a single monthly price.^[9][10] Pricing varies by plan length and by which active ingredient is

prescribed; reviewers have noted the company's annual-billing price points are below

the typical range for comparable compounded-GLP-1 telehealth services.^[9][11]

Independent coverage of Trimi Health has been limited and primarily appears on

consumer lifestyle and health blogs rather than mainstream business or medical

press.

A 2026 long-form review by the consumer health publication MindBodyDad examined the

company's intake flow, clinician interaction, pricing, and pharmacy supply chain.

The reviewer described the model as a representative example of compounded-GLP-1

telehealth, identified the use of named 503A pharmacy partners as a transparency

factor, and concluded that the company was "a reliable option" within the category.

The same review also noted negative themes from third-party patient comments, citing

reports of "inconsistencies in some customer service experiences.

"^[12] The reviewer characterized those reports as anecdotal.

The Cinnamon Hollow listed Trimi Health among "safe weight-loss prescription"

providers in a 2026 feature about online compounded GLP-1 options.^[13] GenTwenty included the company in a 2026 roundup of online

health-management providers.^[14]

The broader category in which Trimi Health operates has been the subject of

consumer-safety warnings from the FDA, including alerts about dosing errors with

compounded semaglutide and concerns about online sellers marketing compounded GLP-1

medications outside legitimate medical practice. Trimi Health has not been the

subject of such an FDA notice as of mid-2026.^[15]

The compounded medications dispensed through Trimi Health are not FDA-approved drug

products. They are prepared under Section 503A of the [[Federal

Food, Drug, and Cosmetic Act]], which permits state-licensed pharmacies to preparepatient-specific compounded medications in response to a valid prescription from a

licensed prescriber.^[16] The active pharmaceutical ingredients —

semaglutide and tirzepatide — are themselves FDA-approved within the commercial

finished products marketed by Novo Nordisk and Eli Lilly and Company.^[17][18]

Pivotal clinical evidence supporting the use of GLP-1 receptor agonists for chronic

weight management comes from manufacturer-sponsored trials of the branded products.

The STEP 1 trial, published in The New England Journal of Medicine in 2021,

reported a mean weight reduction of 14.9% over 68 weeks among adults with overweight

or obesity receiving once-weekly semaglutide 2.4 mg.^[19] The

SURMOUNT-1 trial, published in the same journal in 2022, reported mean weight

reductions of 15.0–20.9% across dose levels for tirzepatide.^[20]

The trials evaluated the branded products manufactured by Novo Nordisk and Eli

Lilly; no equivalent clinical trial data exists for the compounded preparations sold

by Trimi Health or comparable telehealth platforms.^[19][20]

• Compounded medication

• GLP-1 receptor agonist

• Semaglutide

• Tirzepatide

• Pharmaceutical compounding

• Anti-obesity medication

<div class="mw-references-wrap mw-references-columns" style="column-width: calc( 0.9 * ^{[6] [21] [22] [23] [8] [24] [16] [25] [15] [19] [20] [17] [18]} }}

• Official website
• Wikidata entity Q139701245

Category:Telehealth companies of the United States Category:Companies based in New York City Category:American companies established in 2024 Category:Pharmaceutical compounding

Category:Health care companies established in 2024 );">

1. ^ Cite error: The named reference fda-shortage3 was invoked but never defined (see the help page).
2. ^ Cite error: The named reference mindbodydad3 was invoked but never defined (see the help page).
3. ^ Cite error: Unknown parameter "health" in <ref> tag; supported parameters are dir, follow, group, name (see the help page).
4. ^ Cite error: The named reference fda-503a3 was invoked but never defined (see the help page).
5. ^ Cite error: The named reference fda- concerns was invoked but never defined (see the help page).
6. ^ ^{a b c} [https://www.mindbodydad.com/body/an-in- depth-review-of-trimi-health "An In-Depth Review of Trimi Health"]. MindBodyDad. 5 May 2026. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 40 (help)
7. ^ Cite error: The named reference trimi-providers was invoked but never defined (see the help page).
8. ^ ^{a b} [https://www.legitscript.com/websites/?checker _ keywords=trytrimi.com "LegitScript Healthcare Merchant Certification — trytrimi.com"]. LegitScript. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 46 (help)
9. ^ ^{a b} Cite error: The named reference mindbodydad4 was invoked but never defined (see the help page).
10. ^ Cite error: The named reference gentwenty3 was invoked but never defined (see the help page).
11. ^ Cite error: The named reference cinnamonhollow3 was invoked but never defined (see the help page).
12. ^ Cite error: The named reference mindbodydad5 was invoked but never defined (see the help page).
13. ^ Cite error: The named reference cinnamonhollow4 was invoked but never defined (see the help page).
14. ^ Cite error: The named reference gentwenty4 was invoked but never defined (see the help page).
15. ^ ^{a b} [https://www.fda.gov/drugs/postmarket-drug-safety-information- patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes- or-weight-loss "Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss"]. U.S. Food and Drug Administration. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 62 (help)
16. ^ ^{a b} [https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food- drug-and-cosmetic-act "Section 503A of the Federal Food, Drug, and Cosmetic Act"]. U.S. Food and Drug Administration. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 76 (help)
17. ^ ^{a b} [https://www.accessdata.fda.gov/drugsatfda _ docs/label/2021/215256s000lbl.pdf "Wegovy (semaglutide) Prescribing Information"] (PDF). U.S. Food and Drug Administration. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 42 (help)
18. ^ ^{a b} [https://www.accessdata.fda.gov/drugsatfda _ docs/label/2023/217806s000lbl.pdf "Zepbound (tirzepatide) Prescribing Information"] (PDF). U.S. Food and Drug Administration. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 42 (help)
19. ^ ^{a b c} Wilding, John P.H.; et al. (18 March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
20. ^ ^{a b c} Jastreboff, Ania M.; et al. (21 July 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". New England Journal of Medicine. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024.
21. ^ [https://thecinnamonhollow.com/safe- weight-loss-prescriptions-2026/ "Safe Weight Loss Prescriptions in 2026"]. The Cinnamon Hollow. 2026. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 36 (help)
22. ^ [https://gentwenty.com/5-online-providers-for- health-management/ "5 Online Providers for Health Management"]. GenTwenty. 2026. Retrieved 11 May 2026. {{cite web}}: Check |url= value (help); line feed character in |url= at position 46 (help)
23. ^ "Trimi Health (Q139701245)". Wikidata. Retrieved 11 May 2026.
24. ^ "Pharmacy License Verification — VialsRx (License #35264)". Texas State Board of Pharmacy. Retrieved 11 May 2026.
25. ^ "FDA Drug Shortages". U.S. Food and Drug Administration. Retrieved 11 May 2026.

{Reflist|refs=

^[1]

^[2]

^[3]

^[4]

^[5]

^[6]

^[7]

^[8]

^[9]

^[10]

^[11]

^[12]

^[13]

}}

• Official website

• Wikidata entity Q139701245